TGFB1 and non-small cell lung carcinoma: Other IPF treatments targeting galectin-3 (TD139), TGFβ (GC1008), αvβ6 integrin signaling (BG0011, GSK3008348) and inflammatory mediators (QAX576, Carlumab) are currently under clinical development for IPF but may yet find utility as NSCLC therapies (24).